Tag Archives: kite pharma

December, 2017

  • 8 December

    Gilead to Acquire Cell Design Labs for $567 Million

    FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and its cell therapy subsidiary Kite announced today that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts …

October, 2017

August, 2017

July, 2017

May, 2017

  • 30 May

    FDA Grants Priority Review to Kite Pharma’s Non-Hodgkin Lymphoma Drug

    SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for axicabtagene ciloleucel. The submission follows positive data demonstrated with a single infusion of axicabtagene ciloleucel in the …

April, 2017

February, 2017

January, 2017

December, 2016